In an era where innovation is at the forefront of healthcare, one fundamental aspect remains overlooked: accessibility and ...

Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts ...

Pharmaceutical company Apnimed says it's getting positive results from the clinical trials for an oral pill that could treat ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of ...

Dispatch Bio is developing a universal immunotherapy by trying to install a synthetic protein — called the “flare” antigen — ...

The announcement by AstroZeneca follows a growing trend of companies pledging to invest in pharmaceutical manufacturing on American soil in pursuit of appeasing President Donald Trump as he threatens ...

Markets reflect a widespread belief that the US president always chickens out on trade measures. AstraZeneca’s plan to invest ...

The biotech is planning to expand antisense oligonucleotide capabilities and infrastructure on campuses that already produce ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company ...

Adi Ignatius is the editor at large at Harvard Business Review and its former editor in chief.

Financial giants have made a conspicuous bearish move on Ultragenyx Pharmaceutical. Our analysis of options history for Ultragenyx Pharmaceutical (NASDAQ: RARE) revealed 10 unusual trades. Delving ...